DBV: VIPES Data Continues To Show Strong Treatment Effect, Clear Dose Response

(RTTNews) - DBV Technologies (DBVT), a French clinical-stage specialty biopharmaceutical company, developing allergy treatment Viaskin, Monday announced that investigators conducting the company's VIPES study presented additional post-hoc results from this Phase IIb trial for the treatment of peanut allergy. The results showed that increasing the stringency of the responder definition led to a clear treatment dose-response versus placebo in both the study's population and in the children's subgroup.

New scientific data also supports the use of EPIT in the treatment of food allergies versus oral or OIT and sublingual or SLIT immunotherapy. The company remains on track to start its Phase III trial in peanut allergic children, the Peanut EPIT Efficacy and Safety study or PEPITES study, in late 2015.

The company said it has presented and will present clinical and scientific data on EPIT for the treatment of food allergies at the 2015 European Academy of Allergy & Clinical Immunology or EAACI Congress in Barcelona, Spain, that is being held from June 6-10.

New data presented also emphasized Viaskin Peanut's clinical relevance and magnitude of treatment effect, which was observed in VIPES.